OliX and Lilly Enter Global Licensing Agreement for MASH and …
2 days ago · OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016. ... 226950), a leading developer of RNAi therapeutics, today ...
Lilly inks AdvanCell, OliX deals to expand in radiopharma, MASH
1 day ago · Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
1 day ago · Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...
OliX and Lilly Enter Global Licensing Agreement for MASH and …
2 days ago · SEONGNAM, South Korea, February 10, 2025--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016.
Eli Lilly enters global license agreement with OliX for OLX75016
2 days ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly . This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily ...
OliX and Lilly Enter Global Licensing Agreement for MASH and …
2 days ago · OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company (“Lilly”). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH ...
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty
1 day ago · Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016, a ...
Olix, Eli Lilly to develop liver disease drug under $630 million deal …
Olix will use the upfront payment to complete a phase 1 clinical trial for its candidate OLX702A in Australia while Eli Lilly will work on further research, development and commercialization.
Olix, US Eli Lilly Sign MASH and Cardiovascular and Metabolic …
1 day ago · Olix (225950), a breakthrough drug development company based on RNA interference technology, announced today (7th) that it has signed a global licensing agreement with Eli Lilly and Company (hereinafter referred to as Lilly), a leading U.S. pharmaceutical company.. The main goal of this collaboration is to develop and commercialize Olix's OLX702A (chemical name OLX75016), a phase 1 clinical ...
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty …
1 day ago · Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX's OLX75016, a Phase 1 candidate ...
- Some results have been removed